Trial Profile
Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Bisphosphonates; Bisphosphonates
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- 11 Jan 2024 Status changed from active, no longer recruiting to completed.
- 11 Jan 2024 Status changed from active, no longer recruiting to completed.
- 01 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.